Invitation to Participate: SWEET-PLUS Study
You are invited to take part in a research study called SWEET-PLUS (NIHR Research for Patient Benefit: 207952), run by Newcastle and Oxford Brookes Universities. SWEET-PLUS aims to understand experiences of, and factors influencing adherence to, CDK4/6 inhibitors (abemaciclib, ribociclib) among women with ER+ve early breast cancer. We would like to speak with healthcare professionals from a variety of specialisms who encounter patients with ER+ve early breast cancer who have been prescribed CDK4/6 inhibitors (e.g. oncologists, breast surgeons, specialist pharmacists, cancer specialist nurses, etc.). By participating in a one-hour online focus group or interview (whichever you prefer), you can help us understand what support these patients currently receive, and what additional help may be needed.
Please email [email protected] or leave your contact details in the form and a member of the team will be in touch with more details: https://app.onlinesurveys.jisc.ac.uk/s/newcastle/sweet-plus-study-hcp
